Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 4/20 | 0.51 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | CCKAR | P32238 | 4/20 | 0.47 |
| ▸ | CCKBR | P32239 | 4/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6235641 | 0.83 | ITGA4 (0.48) | ITGA4ITGB1ITGB7PTPN1CTSS | |
| SCHEMBL6234383 | 0.83 | ITGA4 (0.48) | ITGA4ITGB7PTPN1CTSSCTSK | |
| SCHEMBL6235727 | 0.83 | ITGA4 (0.54) | ITGA4ITGB1ITGB7PTPN1CTSS | |
| SCHEMBL5163903 | 0.83 | ITGA4 (0.51) | ITGA4ITGB1ITGB7PTPN1CTSS | |
| SCHEMBL30705629 | 0.83 | TACR1 (0.46) | ITGA4ITGB7CTSSCTSKKLK5 | |
| SCHEMBL3531697 | 0.82 | ITGA4 (0.62) | ITGA4ITGB1ITGB7CTSSCTSK | |
| SCHEMBL8304409 | 0.82 | CTSS (0.55) | PTPN1CTSSCTSKKLK5CTSL | |
| SCHEMBL10033679 | 0.81 | CTSS (0.69) | PTPN1CTSSCTSKKLK5CTSL | |
| SCHEMBL1826757 | 0.81 | CTSS (0.69) | PTPN1CTSSCTSKKLK5CTSL | |
| SCHEMBL2802961 | 0.81 | CTSS (0.69) | PTPN1CTSSCTSKKLK5CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916933-B2 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMAN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1244625-B1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | KAPLAN GERALD LEWIS (US) | 2004-07-01 | — | — | US | disclosed |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | KAPLAN GERALD LEWIS (US) | 2002-09-19 | — | — | US | disclosed |
| US-6388084-B1 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMANN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | VCAM1, ICAM1, SELPLG | ITGA4 8/4885ITGB1 13/4885ITGB7 99/4885 |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | VCAM1, ICAM1, SELPLG | ITGA4 8/4885ITGB1 13/4885ITGB7 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.